Apogee Therapeutics(APGE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

APGE Apogee Therapeutics

盘前交易 06-23 09:03:59 EDT

132.55

+42.17

+46.66%

盘前132.54

-0.01-0.01%

09:03 EDT

最高133.00	最低132.45	成交量6,166万
今开132.60	昨收90.38	日振幅0.61%
总市值99.86亿	流通市值93.19亿	总股本7,534万
成交额81.82亿	换手率87.70%	流通股本7,031万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"APGE","market":"US","secType":"STK","nameCN":"Apogee Therapeutics","latestPrice":132.55,"timestamp":1782158400000,"preClose":90.38,"halted":0,"volume":61663544,"hourTrading":{"tag":"盘前","latestPrice":132.54,"preClose":132.55,"latestTime":"09:03 EDT","volume":26867,"amount":3561129.2335300003,"timestamp":1782219816563,"change":-0.01,"changeRate":-0.000075,"amplitude":0.011301},"delay":0,"changeRate":0.4665855277716311,"floatShares":70308023,"shares":75339900,"eps":-4.320623,"marketStatus":"盘前交易","change":42.17,"latestTime":"06-23 09:03:59 EDT","open":132.6,"high":133,"low":132.45,"amount":8181564032.30712,"amplitude":0.006085,"askPrice":132.54,"askSize":50,"bidPrice":132.52,"bidSize":1820,"shortable":3,"etf":0,"ttmEps":-4.320623,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782221400000},"marketStatusCode":1,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":132.55,"preHourTrading":{"tag":"盘前","latestPrice":132.54,"preClose":132.55,"latestTime":"09:03 EDT","volume":26867,"amount":3561129.2335300003,"timestamp":1782219816563,"change":-0.01,"changeRate":-0.000075,"amplitude":0.011301},"postHourTrading":{"tag":"盘后","latestPrice":132.5266,"preClose":132.55,"latestTime":"19:52 EDT","volume":711193,"amount":94268836.2831,"timestamp":1782172361173,"change":-0.0234,"changeRate":-0.000177,"amplitude":0.001509},"volumeRatio":49.32243065742139,"impliedVol":0.0947,"impliedVolPercentile":0.004},"requestUrl":"/m/hq/s/APGE","defaultTab":"news","newsList":[{"id":"1146210826","title":"AbbVie以109亿美元收购Apogee Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=1146210826","media":"老虎资讯综合","labels":["corporation"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146210826?lang=zh_cn&edition=full","pubTime":"2026-06-23 08:57","pubTimestamp":1782176244,"startTime":"0","endTime":"0","summary":"AbbVie同意以约10.9 billion美元全现金收购Apogee Therapeutics，以加强其免疫学产品组合，并加快其在呼吸领域的临床布局。双方于周一联合声明表示，AbbVie将以每股135.11美元现金收购Apogee。Apogee股价于周一交易时段飙升约47%，AbbVie则升3.7%。是次交易将使AbbVie取得Apogee处于临床阶段、用于治疗炎症及免疫疾病的研发产品组合。AbbVie行政总裁Robert Michael于声明中表示，收购Apogee进一步巩固公司现有领导地位，并强化向患者提供创新药物的能力，同时为股东创造长期价值。","market":"us","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"324431b18d184842b2237adf08e51534","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"AbbVie以109亿美元收购Apogee Therapeutics","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","ABBV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645078578","title":"109亿美元豪赌下一代“药王”！艾伯维溢价49%收购Apogee，剑指赛诺菲Dupixent","url":"https://stock-news.laohu8.com/highlight/detail?id=2645078578","media":"智通财经","labels":["corporation","merge"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645078578?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:05","pubTimestamp":1782137159,"startTime":"0","endTime":"0","summary":"根据协议条款，艾伯维将以每股135.11美元的现金价格收购Apogee所有已发行普通股，总股权价值约为109亿美元。艾伯维预计，2026年Skyrizi销售额约为216亿美元，Rinvoq约为102亿美元，两款药物合计将贡献超过310亿美元的年收入，目前已合计占艾伯维季度总营收的约44%。艾伯维方面则表示，Apogee的管线资产具有“重磅炸弹级别的集体峰值销售潜力”。艾伯维计划通过债务融资来完成此次收购。艾伯维以109亿美元收购Apogee，本质上是一场关于时间差的博弈。","market":"fut","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457208.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"109亿美元豪赌下一代“药王”！艾伯维溢价49%收购Apogee，剑指赛诺菲Dupixent","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0158827948.USD","LU0058720904.USD","BK4533","LU0098860793.USD","LU0069063385.USD","LU0943347566.SGD","LU0198837287.USD","IE0002141913.USD","LU1430594728.SGD","LU0320765646.SGD","IE0009355771.USD","LU1057294990.SGD","IE000F7OJYX1.SGD","LU0820561909.HKD","LU0203345920.USD","LU1061106388.HKD","BK4559","LU2087621335.USD","LU0823416689.USD","BK4566","LU0882574055.USD","LU2357627491.SGD","APGE","IE00B3PB1722.GBP","LU1983299246.USD","LU0170899867.USD","LU0942090050.USD","LU0912757837.SGD","LU0029864427.USD","LU0985320562.USD","LU0965509010.AUD","LU2468319806.SGD","LU2089283258.USD","LU0310799852.SGD","LU1989772923.USD","LU0472753341.HKD","LU0820561818.USD","LU0511384066.AUD","LU0795875086.SGD","LU0965509101.SGD","LU0203347892.USD","LU1003077747.HKD","ABBV","LU1934455277.USD","IE00BVYPNV92.GBP","LU0545039389.USD","BK4550","LU1244550494.USD","SG9999011175.SGD","IE000MB6IJN5.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1183626538","title":"异动解读｜Apogee Therapeutics盘中上涨46.61%，艾伯维以109亿美元达成收购协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1183626538","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183626538?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:40","pubTimestamp":1782135601,"startTime":"0","endTime":"0","summary":"6月22日，Apogee Therapeutics盘中上涨46.61%，报132.665美元/股，成交额23.11亿美元。消息面上，艾伯维正式宣布以每股135.11美元现金收购Apogee Therapeutics，总股权价值约109亿美元，较前一交易日收盘价溢价约60%。这是艾伯维近六年来最大规模的并购交易。该交易旨在补强艾伯维免疫学管线，应对Humira遭遇生物类似药侵蚀的压力。Canaccord Genuity已将评级从买入下调至持有，目标价上调至135.11美元，与收购价一致。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104351212","title":"Canaccord Genuity下调Apogee Therapeutics评级至持有，目标价上调至135.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104351212","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104351212?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:21","pubTimestamp":1782134474,"startTime":"0","endTime":"0","summary":"投资机构Canaccord Genuity调整了对生物技术公司Apogee Therapeutics (APGE)的股票评级。该机构将评级从“买入”下调至“持有”，但同时将其目标股价从130美元上调至135.11美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APGE","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150642212","title":"Apogee Therapeutics将根据IL-31R许可协议向Paragon支付高达2325万美元的里程碑款项——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1150642212","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150642212?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:25","pubTimestamp":1782127519,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会提交的文件，Apogee Therapeutics公司已同意，依据其与Paragon达成的IL-31R许可协议，向后者支付最高可达2325万美元的里程碑款项。该协议明确了在药物研发与商业化进程中达成特定目标时，Apogee需履行的财务义务。此次披露的金额上限涵盖了协议中设定的各项里程碑事件，凸显了Apogee为推进其IL-31R相关项目所承诺的潜在投资规模。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APGE","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645943014","title":"溢价高达60%！艾伯维拟109亿美元收购Apogee，最快今日官宣","url":"https://stock-news.laohu8.com/highlight/detail?id=2645943014","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645943014?lang=zh_cn&edition=full","pubTime":"2026-06-22 08:30","pubTimestamp":1782088205,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据知情人士透露，艾伯维正接近达成一项斥资近 110 亿美元收购抗炎药物研发商 Apogee Therapeutics的协议。这笔交易预计将成为这家制药巨头自 2019 年以来规模最大的补强式收购。知情人士称，根据正在讨论的收购条款，Apogee的投资者将获得 109 亿美元的现金，这意味着较该公司最近的收盘价有约 60% 的溢价。一笔潜在的交易将进一步增强艾伯维的免疫学产品线。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4534","LU0545039389.USD","BK4533","APGE","LU0661504455.SGD","LU2133065610.SGD","LU0310799852.SGD","IE00B19Z3B42.SGD","LU1670628061.USD","IE00B4R5TH58.HKD","LU1983299246.USD","LU2089984988.USD","LU2468319806.SGD","LU0511384066.AUD","LU0861579265.USD","LU1718418525.SGD","LU0689626769.HKD","IE0009355771.USD","LU1496350502.SGD","LU2237443895.HKD","LU0289961442.SGD","LU1162221912.USD","LU0942090050.USD","LU1989772840.SGD","IE00BJT1NW94.SGD","BK4585","LU1732799900.SGD","LU1989772923.USD","IE00BFTCPJ56.SGD","LU2112291526.USD","LU1934455194.USD","BK4550","LU0029864427.USD","LU2237443465.HKD","LU0689472784.USD","IE00BVYPNV92.GBP","ABBV","LU0203345920.USD","LU0943347566.SGD","LU1244550577.SGD","LU1291159041.SGD","LU1551013425.SGD","IE0002270589.USD","LU1929549753.HKD","IE00BBT3K403.USD","IE000SO60NU8.SGD","LU1670627923.USD","LU0738911758.USD","LU1267930490.SGD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125243123","title":"Apogee Therapeutics 股价盘前重挫19%：特应性皮炎抗体中期试验结果与13亿美元黑石融资合作引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1125243123","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125243123?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:46","pubTimestamp":1779878793,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics 的股价在盘前交易时段大幅下跌19%，这一市场反应紧随其特应性皮炎抗体药物中期临床试验结果的公布，以及一项与黑石集团达成的13亿美元融资合作消息之后。\n该公司专注于开发针对炎症和免疫学疾病的疗法。此次股价波动凸显了市场对其核心产品临床数据以及大规模融资合作细节的复杂解读。投资者正在仔细评估试验结果对未来商业化前景的影响，同时也权衡巨额融资合作可能带来的股权稀释效应与长期发展资源。\n尽管面临股价压力，但这项与知名投资机构黑石达成的重大融资合作，也为 Apogee 提供了推进其研发管线的显著资金支持。市场参与者将持续关注公司后续的数据披露及战略执行情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182689606","title":"Apogee Therapeutics 与黑石生命科学就Zumilokibart销售达成收入分成协议，后者将支付1亿美元预付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1182689606","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182689606?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:42","pubTimestamp":1779878539,"startTime":"0","endTime":"0","summary":"根据一份向美国证券交易委员会提交的文件，生物技术公司Apogee Therapeutics Inc. 与黑石集团旗下的投资平台黑石生命科学达成了一项合作协议。根据协议条款，黑石生命科学将向Apogee支付高达1亿美元的预付款，以换取其核心候选药物Zumilokibart未来销售收入的份额。这项交易为Apogee提供了重要的非稀释性资金，支持其继续推进Zumilokibart的临床开发。Zumilokibart是一种用于治疗特应性皮炎等炎症性疾病的潜在疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168978323","title":"Apogee Therapeutics获首轮4亿美元预批准融资，分三期支付并与研发里程碑挂钩","url":"https://stock-news.laohu8.com/highlight/detail?id=1168978323","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168978323?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:34","pubTimestamp":1779878049,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics Inc.宣布获得首轮高达4亿美元的预批准融资。该笔资金将依据公司关键研发里程碑的达成情况，分三期进行支付。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN8TJ469.HKD","IE00B64PRP62.GBP","APGE","IE00BBT3K403.USD","IE00BLSP4239.USD","BK4588","IE00BLSP4452.SGD","BK4135","BK4139","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0053671581.USD","BX","BK4585","IE0004445239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103498978","title":"Apogee Therapeutics Inc 达成协议 包含最高8亿美元合成特许权使用费及最高5亿美元高级债务","url":"https://stock-news.laohu8.com/highlight/detail?id=1103498978","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103498978?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:32","pubTimestamp":1779877970,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics Inc 宣布达成一项融资协议，该协议结构包含两部分：最高可达8亿美元的合成特许权使用费融资，以及最高可达5亿美元的高级债务融资。这一综合性融资安排旨在为公司提供灵活且大规模的资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE0004445239.USD","IE00BGHQF748.EUR","APGE","IE00BBT3K403.USD","IE00BN8TJ469.HKD","LU0053671581.USD","IE00B3QW5Z07.USD","IE00BLSP4452.SGD","BK4585","BK4135","BK4139","BX","IE00B64PRP62.GBP","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171805318","title":"美国食品药品监督管理局批准Zumilokibart后，Apogee Therapeutics Inc可获得高达4亿美元额外资金","url":"https://stock-news.laohu8.com/highlight/detail?id=1171805318","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171805318?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:32","pubTimestamp":1779877936,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics Inc宣布，一旦其候选药物Zumilokibart获得美国食品药品监督管理局（FDA）的批准，公司将有权获得高达4亿美元的额外融资。这一融资安排将为Apogee Therapeutics在Zumilokibart获批后的商业化进程提供关键的资金支持，助力公司推进该药物的市场推广和后续研发工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0004445239.USD","BK4588","IE00B64PRP62.GBP","IE00BBT3K403.USD","APGE","BK4585","IE00B3QW5Z07.USD","IE00BLSP4452.SGD","IE00BGHQF748.EUR","LU0053671581.USD","BX","BK4135","BK4139","IE00BLSP4239.USD","IE00BN8TJ469.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128569396","title":"Apogee Therapeutics公布Zumilokibart治疗中重度特应性皮炎II期APEX试验B部分诱导期剂量优化16周积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1128569396","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128569396?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:30","pubTimestamp":1779877823,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics公司宣布，其候选药物Zumilokibart用于治疗中重度特应性皮炎的II期APEX临床试验，在B部分（诱导期剂量优化）取得了积极的16周结果。\n该试验数据表明，在16周的诱导治疗期内，不同剂量组的Zumilokibart在改善疾病严重程度和关键症状方面均显示出令人鼓舞的疗效与良好的耐受性。这些结果为确定后续临床开发的最佳给药方案提供了重要依据，进一步支持了该药物在治疗这一慢性、难治性皮肤病方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APGE","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184384981","title":"Apogee Therapeutics完成公开募股，承销商全额行使超额配售权，募集资金总额达4.03亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184384981","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184384981?lang=zh_cn&edition=full","pubTime":"2026-03-27 04:03","pubTimestamp":1774555392,"startTime":"0","endTime":"0","summary":"生物制药公司Apogee Therapeutics, Inc.近日宣布，其公开发行项目已正式完成，承销商全额行使了超额配售选择权，额外购入公司股份。本次发行累计募集资金总额高达4.03亿美元。\n此次公开募股的成功，不仅彰显了市场对Apogee Therapeutics研发前景的信心，也为公司后续的药物研发与临床推进提供了充足的资金保障。公司表示，所募资金将主要用于推进其在研管线项目的开发，并支持企业日常运营及潜在的战略合作机会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157135932","title":"Apogee Therapeutics公布3.5亿美元承销公开发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1157135932","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157135932?lang=zh_cn&edition=full","pubTime":"2026-03-25 09:55","pubTimestamp":1774403756,"startTime":"0","endTime":"0","summary":"旧金山和波士顿，2026年3月24日——临床阶段生物技术公司Apogee Therapeutics, Inc.今日宣布，其先前公布的承销公开发行已完成定价。此次发行以每股70.00美元的公开发行价格，共计发行5,000,000股普通股。在扣除承销折扣、佣金以及Apogee应承担的其他发行费用之前，公司预计从此次发行中获得的总收益约为3.5亿美元。此外，Apogee已授予承销商一项为期30天的选择权，允许其以公开发行价额外购买最多750,000股普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","USA","LU0053671581.USD","BK4139","APGE","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115413918","title":"Apogee Therapeutics盘中飙升16.6% 公司宣布湿疹药物中期试验展现持久疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1115413918","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115413918?lang=zh_cn&edition=full","pubTime":"2026-03-23 18:51","pubTimestamp":1774263071,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics公司股价在盘前交易中大幅上涨16.6%，此前该公司宣布其湿疹治疗药物在中期临床试验中展现出持久的疗效。这一积极数据点燃了投资者对这款创新疗法的期待，市场反应热烈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","BK4139","APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167148054","title":"Apogee Therapeutics：3个月与6个月剂量治疗下病灶及瘙痒指标反应持续深化","url":"https://stock-news.laohu8.com/highlight/detail?id=1167148054","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167148054?lang=zh_cn&edition=full","pubTime":"2026-03-23 18:34","pubTimestamp":1774262099,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics宣布，其临床研究数据显示，在3个月和6个月的给药周期后，患者病灶改善程度与瘙痒控制指标均呈现持续深化趋势。这一进展凸显了长期治疗对疾病关键症状的累积增效作用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192197415","title":"Apogee Therapeutics公布Zumilokibart（APG777）II期试验52周积极数据，显示中重度特应性皮炎患者每3个月及6个月给药可维持并加深疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1192197415","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192197415?lang=zh_cn&edition=full","pubTime":"2026-03-23 18:33","pubTimestamp":1774262037,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics（股票代码：APGE）近日宣布，其候选药物Zumilokibart（APG777）在治疗中重度特应性皮炎的II期临床试验中，获得了52周的积极数据。研究结果表明，无论是每3个月还是每6个月一次的给药方案，均能有效维持并持续加深患者的临床应答，展现出持久的疗效潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APGE","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194423233","title":"Apogee Therapeutics公司——APEX B部分16周诱导研究结果预计2026年第二季度公布，三期临床试验将于2026年下半年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1194423233","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194423233?lang=zh_cn&edition=full","pubTime":"2026-03-23 18:33","pubTimestamp":1774261990,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics公司宣布，其APEX研究B部分针对16周诱导期的数据结果预计在2026年第二季度揭晓。紧随其后，公司计划于2026年下半年正式启动三期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166710296","title":"Apogee Therapeutics公司——Zumilokibart耐受性良好，安全性与同类药物一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1166710296","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166710296?lang=zh_cn&edition=full","pubTime":"2026-03-23 18:32","pubTimestamp":1774261967,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics公司宣布，其研发的Zumilokibart在临床试验中表现出良好的耐受性，且安全性特征与同类药物保持一致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0053671581.USD","APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160404547","title":"Apogee Therapeutics公布潜在同类最佳抗IL-13抗体Zumilokibart（APG777）治疗轻中度哮喘患者的1B期试验积极中期结果，并展望2026年里程碑与前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1160404547","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160404547?lang=zh_cn&edition=full","pubTime":"2026-01-06 19:00","pubTimestamp":1767697219,"startTime":"0","endTime":"0","summary":"生物制药公司Apogee Therapeutics近日披露了其核心候选药物Zumilokibart（研发代号APG777）在轻中度哮喘患者中开展的1B期临床试验的中期分析数据，结果显示出积极信号。该抗体药物靶向IL-13通路，被公司定位为潜在“同类最佳”疗法。\n与此同时，Apogee还明确了2026年的关键研发节点与战略展望，为后续临床推进和商业化布局奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apogeetherapeutics.com","stockEarnings":[{"period":"1week","weight":0.5379},{"period":"1month","weight":0.6332},{"period":"3month","weight":0.8158},{"period":"6month","weight":0.6974},{"period":"1year","weight":2.159},{"period":"ytd","weight":0.7561}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.1396},{"period":"6month","weight":0.0782},{"period":"1year","weight":0.2526},{"period":"ytd","weight":0.0916}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Apogee Therapeutics, Inc.于2023年6月9日作为一家特拉华州公司成立，与此次发行有关，作为一家控股公司，将全资拥有Apogee Therapeutics，LLC，并间接拥有其子公司。该公司是一家生物技术公司，致力于开发用于治疗特应性皮炎、慢性阻塞性肺病及相关炎症和免疫学适应症的差异化生物制剂，这些适应症的需求尚未得到满足。该公司的抗体项目旨在克服现有疗法的局限性，针对的是成熟的作用机制，并结合先进的抗体工程来优化半衰期。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.006689},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.043968},{"month":3,"riseRate":1,"avgChangeRate":0.433037},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.069219},{"month":5,"riseRate":0,"avgChangeRate":-0.056063},{"month":6,"riseRate":0.666667,"avgChangeRate":0.220402},{"month":7,"riseRate":0.5,"avgChangeRate":0.059284},{"month":8,"riseRate":0.666667,"avgChangeRate":0.024428},{"month":9,"riseRate":0.666667,"avgChangeRate":0.056277},{"month":10,"riseRate":0.333333,"avgChangeRate":0.038958},{"month":11,"riseRate":0.666667,"avgChangeRate":0.091668},{"month":12,"riseRate":1,"avgChangeRate":0.161393}],"exchange":"NASDAQ","name":"Apogee Therapeutics","nameEN":"Apogee Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apogee Therapeutics(APGE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Apogee Therapeutics(APGE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Apogee Therapeutics,APGE,Apogee Therapeutics股票,Apogee Therapeutics股票老虎,Apogee Therapeutics股票老虎国际,Apogee Therapeutics行情,Apogee Therapeutics股票行情,Apogee Therapeutics股价,Apogee Therapeutics股市,Apogee Therapeutics股票价格,Apogee Therapeutics股票交易,Apogee Therapeutics股票购买,Apogee Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apogee Therapeutics(APGE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Apogee Therapeutics(APGE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}